Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

CD19 t-haNK

Cell therapy (CAR-NK) · Kills target cells, directed at CD19 · developed by ImmunityBio

Phase 2 Most advanced trial

IBRX Developer

2 Registered trials

What is CD19 t-haNK?

CD19 t-haNK is an allogeneic NK cell therapy engineered to express a CAR targeting CD19, along with endoplasmic reticulum-retained IL-2 and high-affinity FcγRIIIa/CD16a for enhanced antibody-dependent cellular cytotoxicity. It is being studied in relapsed or refractory B-cell non-Hodgkin lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: CD19t-haNK suspension
Drug type: Cell therapy (CAR-NK)
Targets: CD19 (antigen)
Mechanism: Kills target cells, directed at CD19
Pathways: ADCC, NK cell activation
Therapy area: Oncology
Developer: ImmunityBio, Inc. (IBRX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07125872	Phase 2	Relapsed B-Cell Non Hodgkin Lymphoma	Recruiting	IBRX
NCT05618925	Phase 1	Non Hodgkin's Lymphoma Refractory/Relapsed	Recruiting	IBRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non Hodgkin's Lymphoma Refractory/RelapsedRelapsed B-Cell Non Hodgkin Lymphoma

Other drugs acting on CD19

Blinatumomab FDA approved Inebilizumab FDA approved Loncastuximab tesirine FDA approved Budoprutug Phase 1/2 MK-1045 Phase 2/3

More from ImmunityBio

Nogapendekin Alfa Inbakicept FDA approved 5Fluorouracil Phase 2 AAHI-SC2 Phase 1/2 AAHI-SC3 Phase 1/2 Adenoviral Vector Ad5-CEA Vaccine Phase 1/2 agenT-797 Phase 3 Aldoxorubicin Phase 2 ETBX-021 Phase 1/2 ETBX-051 Phase 1/2 ETBX-061 Phase 1/2 ETBX-071 Phase 2 GI-4000 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the IBRX page.

Follow IBRX, the company behind CD19 t-haNK

See IBRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IBRX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z